Targeting cytokine and chemokine signaling pathways for cancer therapy.

Signal Transduct Target Ther · 2024 · PMC11275440 · PMID 39034318

Europe PMC DOI

hedged sentence

0.1000

closest p · 2.0× alpha

0.1000

boldest claim

The sentences

showed a trendP = 0.10so close (0.05 < p ≤ 0.1)

498 Additionally, this group showed a trend towards superior 2-year survival ( P = 0.10), with median OS of 39.1 months for 10 μM trabedersen, 35.2 months for 80 μM trabedersen, and 21.7 months for chemotherapy. 498 In the realm of cancer vaccines, belagenpumatucel-L, a vaccine by NovaRx composed of NSCLC cells with a TGF-β2 antisense gene,

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.